United States Second Circuit

Reset A A Font size: Print

US ex rel. Polansky v. Pfizer, 14-4774

In an action brought under the False Claims Act (FCA) and state analog causes of action against plaintiff's former employer, alleging it improperly marketed Lipitor, a popular statin, as appropriate for patients whose risk factors and cholesterol levels fall outside the National Cholesterol Education Program Guidelines, the District Court's dismissal of the action is affirmed where the Guidelines are not incorporated into the Lipitor label.

Appellate Information

  • Decided
  • Published 2016/05/17




  • United States Second Circuit